Aprea Therapeutics is a clinical-stage biopharmaceutical company. Co.'s primary synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DNA damage response (DDR). Co. is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Co.'s primary WEE1 inhibitor product candidate is ATRN-1051. In addition, Co. has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. Finally, Co. also has an early preclinical research program, which is aimed at identification of inhibitors of a distinct protein involved in DDR. The APRE YTD return is shown above.
The YTD Return on the APRE YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether APRE YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the APRE YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|